Nexium Discounts Still Capturing “Value” For Brand, AstraZeneca Says
Executive Summary
AstraZeneca's Nexium continues to gain share in the proton pump inhibitor category at prices that reflect the "value" of the brand, the company said during an April 29 earnings call
You may also be interested in...
Astra Joint Venture Keeps Paying Dividends For Merck; “True Up” Due In 2008
AstraZeneca is still estimating that its final payment in the break-up of the Merck joint venture will be $4.7 bil. in 2008
Wyeth Protonix Is Price Leader For PPIs Under Medicare Discount Cards
Wyeth's Protonix is carrying the best price for prescription proton pump inhibitors under the Medicare drug discount card program
Astra Joint Venture Keeps Paying Dividends For Merck; “True Up” Due In 2008
AstraZeneca is still estimating that its final payment in the break-up of the Merck joint venture will be $4.7 bil. in 2008